- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- NCPA: Community pharmacy has historically helped patients as they transition to new health plans
- FDA advisory panel to consider OTC status of NSAIDs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating major depressive disorder, the agency said Friday.
The FDA announced the approval of Viibryd (vilazodone hydrochloride), made by New Haven, Conn.-based PGxHealth.
“Major depressive disorder is disabling and prevents a person from functioning normally,” FDA Division of Psychiatry Products director Thomas Laughren said. “Medications affect everyone differently, so it’s important to have a variety of treatment options available to patients who suffer from depression.”